Xeris Biopharma officer sells 16,667 shares

Xeris Biopharma Holdings officer Beth Hecht completed an open-market sale of 16,667 shares of common stock at a weighted average price of $6.2282 per share.

Rhea-AI Filing Summary

Xeris Biopharma Holdings officer Beth Hecht completed an open-market sale of 16,667 shares of common stock at a weighted average price of $6.2282 per share. After the sale, she directly holds 1,193,173 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 16,667 shares

Net Sell 1 txn

Insider Hecht Beth

Role See Remarks

Sold 16,667 shs ($104K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,667	$6.2282	$104K

Holdings After Transaction: Common Stock — 1,193,173 shares (Direct)

Footnotes (2)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.100 to $6.320, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 16,667 shares Weighted average sale price: $6.2282 per share Post-transaction holdings: 1,193,173 shares +1 more

4 metrics

Shares sold 16,667 shares Open-market sale on May 1, 2026

Weighted average sale price $6.2282 per share Common stock sale

Post-transaction holdings 1,193,173 shares Shares directly held after sale

Price range of individual sales $6.100–$6.320 per share Multiple trades within this range

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type: non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xeris Biopharma (XERS) report for Beth Hecht?

Beth Hecht reported an open-market sale of 16,667 Xeris Biopharma common shares. The transaction was recorded as a code S sale, indicating a sale in the open market or a private transaction, and is disclosed as a routine insider trade in the Form 4 filing.

At what price were the Xeris Biopharma (XERS) shares sold in this Form 4?

The shares were sold at a weighted average price of $6.2282 per Xeris Biopharma share. A footnote explains that individual trades occurred between $6.100 and $6.320, and detailed trade-by-trade pricing is available upon request from the company or the SEC staff.

How many Xeris Biopharma (XERS) shares does Beth Hecht hold after the sale?

Following the reported sale, Beth Hecht directly holds 1,193,173 Xeris Biopharma common shares. This post-transaction holding figure, disclosed in the Form 4, shows that the 16,667 shares sold represent a small portion of her overall direct equity position in the company.

Was the Xeris Biopharma (XERS) insider trade made under a Rule 10b5-1 plan?

Yes, the filing states the transaction was effected under a Rule 10b5-1 trading plan. Such plans are pre-arranged programs that schedule trades in advance, helping insiders diversify or manage holdings while reducing concerns about trading on nonpublic information.

What does transaction code "S" mean in the Xeris Biopharma (XERS) Form 4?

Transaction code "S" in this Form 4 indicates a sale of common stock in the open market or a private transaction. The filing classifies the event as a non-derivative transaction and confirms it as an open-market sale rather than an option exercise or gift.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 05:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S(1)		16,667	D	$6.2282(2)	1,193,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.100 to $6.320, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)